The Cancer Drug Development Forum (CDDF) held a live webinar titled “Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe” on Tuesday, June 25 2024, at 16:00 (CEST) / 10:00 (EST).
WEBINAR OUTLINE
Under the joint leadership of the European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC), the Cancer Medicines Forum (CMF) serves as a pioneering initiative. Its primary goal is to seamlessly integrate the academic sector’s contributions into the regulatory decision-making process. Acting as a unique conduit between regulatory authorities and academic clinical research, the Cancer Medicines Forum facilitates the exchange of insights and expertise.
The deliverables of the Cancer Medicines Forum are strategically tailored to support policy decisions aimed at enhancing treatment optimization across Europe. Emphasizing post-licensing inquiries grounded in clinically relevant endpoints, the Cancer Medicines Forum endeavours to shape policy that prioritizes patient welfare within the healthcare landscape.
During the hybrid workshop held on April 5 2024, the Cancer Medicines Forum presented its astute observations and preliminary solutions to address treatment optimization.
This webinar, organized by the Cancer Drug Development Forum, provide a platform for Denis Lacombe (EORTC) to share the recommendations stemming from the workshop’s discussions.
Agenda: (CEST time zone)
16:00 – 16:05 Introduction – Rosa Giuliani (CDDF, UK)
16:05 – 16:30 Lecture by Denis Lacombe (EORTC, BE)
16:30 – 17:00 Panel Discussion – moderated by Rosa Giuliani (CDDF, UK) & Daniel Goldstein (Rabin Medical Center, IL)
WEBINAR OUTPUT
Denis Lacombe - Speaker
Denis Lacombe graduated with his MD from the University of Marseilles (France) in 1988 and obtained a Master Post-Doctoral Fellowship at The Roswell Park Cancer Institute (Buffalo, NY USA) for research in pharmacology and pharmacokinetics from 1989 to 1991. From 1991 to 1993, he worked as a Clinical Research Advisor in charge of the development of a new drug in oncology in the pharmaceutical industry.
Dr Lacombe joined the EORTC in 1993 as a research fellow and quickly became a very active and productive Clinical Research Physician involved in the conduct of clinical research from protocol development through publication for many oncology indications from phase I to phase III. Dr Lacombe contributed to the strategic evolution of the EORTC pan-European clinical and translational research infrastructure as well as developing partnerships with multiple stakeholders.
Dr Lacombe rose to the position of Director of EORTC Headquarters in 2010, was appointed Director General in April 2015 and Chief Executive Officer in June 2021. In his current position, Denis Lacombe leads all activities promoting the EORTC as a major European organization in Cancer Clinical and Translational Research, including scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as internal and external communications.
Dr Lacombe is the author of well over 100 peer-reviewed publications and communications.
Daniel Goldstein - Moderator
Daniel Goldstein MD is a medical oncologist and internist at Rabin Medical Center in Israel, as well as a Professor in Medical Oncology at Tel Aviv University. He is also the medical director of drug and technology policies, in the community division of Clalit Health Services. He treats patients, teaches trainees, and researches and implements economically sustainable policies for cancer care.
Rosa Giuliani - Moderator
Rosa Giuliani is a consultant in medical oncology currently working at Guy’s and St Thomas’ NHS Foundation Trust. She is a co-chair of the Healthcare Professional Working Party (HCPWP) at European Medicines Agency (EMA) and a Member of the EMA Cancer Medicines Forum. In the past, she was Director of Cancer Policy at the European Society for Medical Oncology from 2020 to 2022 and also Core member of the Scientific Advisory Group-Oncology (SAG-O) at the EMA from 2012 to 2021.
She earned her medical degree from the University of Rome, La Sapienza, in 1996 and completed the specialty training in medical oncology in 2000. She dedicated several years specializing in the treatment of breast cancer at the MD Anderson Cancer Centre, Houston, TX (1999), at the Breast Unit of the Jules Bordet Institute in Brussels (2001-2003), at the Cancer Cell Biology Dept of Hammersmith Hospital (2005-2006) and at the Breast Unit of Charing Cross Hospital (2008) in London.